Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues

Liu,Xiaoxia; Cao,Lingling; Ni,Jinsong; Liu,Ning; Zhao,Xiaoming; Wang,Yanfang; Zhu,Lin; Wang,Lingyao; Wang,Jin; Yue,Ying; Cai,Yong; Jin,Jingji

doi:10.3892/ijo.2013.2124

Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues

Authors:
- Xiaoxia Liu
- Lingling Cao
- Jinsong Ni
- Ning Liu
- Xiaoming Zhao
- Yanfang Wang
- Lin Zhu
- Lingyao Wang
- Jin Wang
- Ying Yue
- Yong Cai
- Jingji Jin
View Affiliations

Affiliations: Department of Gynecologic Oncology, The First Clinical Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China, Department of Pathology, The First Clinical Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Urology, The First Clinical Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: October 3, 2013 https://doi.org/10.3892/ijo.2013.2124
Pages: 1925-1934

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human BCCIP, a protein which interacts with BRCA2 and CDKN1A (Cip1, p21), has been implicated in many cellular processes including cell cycle regulation, DNA recombination and damage repair, telomere maintenance, embryonic development and genomic stability. BCCIP gene expression, which is an important BRCA2 cofactor in tumor suppression, has been identified in some primary cancers. Thus, we investigated the role of BCCIP expression in a large sample of clinically diagnosed primary ovarian cancer, renal cell carcinoma (RCC) and colorectal cancer (CRC) tissues. Using clinically diagnosed frozen primary cancer tissues, quantitative PCR (qPCR), western blot analysis (WB) and immunohistochemical staining (IHC) approaches were used to detect and measure gene expression. Reduced BCCIP gene expression in ovarian cancer, RCC and CRC tissues occurred in 74, 89 and 75% of tissue samples, respectively. qPCR analysis of mRNA expression in 54 ovarian cancer, 50 RCC and 44 CRC samples revealed significant (>2-fold decreased) BCCIP downregulation in 56, 70 and 46% of tissue samples, respectively. Although BCCIP expression in three different tumor tissues decreased, the relationship between BCCIP expression and clinicopathological features of each cancer was distinct. Compared to normal tissues, BCCIP expression in ovarian cancers was significantly downregulated in serous, endometrioid and mucinous carcinomas. Downregulation of BCCIP expression was strongly associated with clear cell RCC (ccRCC) and Fuhrman tumor grading, but significant differences in BCCIP expression between CRC and matched normal tissues occurred only in male CRC tissues (p<0.05) and in tissue with a T4 tumor stage (p<0.01). Thus, BCCIP protein was chiefly reduced in ovarian cancer and RCC tissue samples (p<0.05). BCCIP gene expression was downregulated in human ovarian cancer, RCC and CRC tissues, suggesting a role for the gene in the pathogenesis of these cancers.

View Figures

View References

1.	Ono T, Kitaura H, Ugai H, Murata T, Yokoyama KK, Iguchi-Ariga SM and Ariga H: Tok-1, a novel p21^Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase. J Biol Chem. 275:31145–31154. 2000.PubMed/NCBI
2.	Liu J, Yuan Y, Huan J and Shen Z: Inhibition of breast and brain cancer cell growth by BCCIPα, an evolutionarily conserved nuclear protein that interacts with BRCA2. Oncogene. 20:336–345. 2001.PubMed/NCBI
3.	Meng X, Liu J and Shen Z: Genomic structure of the human BCCIP gene and its expression in cancer. Gene. 302:139–146. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Fan J, Wray J, Meng X and Shen Z: BCCIP is required for the nuclear localization of the p21 protein. Cell Cycle. 8:3019–3024. 2009.PubMed/NCBI
5.	Lu H, Guo X, Meng X, Liu J, Allen C, Wray J, Nickoloff JA and Shen Z: The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol Cell Biol. 25:1949–1957. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Meng X, Liu J and Shen Z: Inhibition of G1 to S cell cycle progression by BCCIPβ. Cell Cycle. 3:343–348. 2004.PubMed/NCBI
7.	Meng X, Lu H and Shen Z: BCCIP functions through p53 to regulate the expression of p21^Waf1/Cip1. Cell Cycle. 3:1457–1462. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Meng X, Fan J and Shen Z: Roles of BCCIP in chromosome stability and cytokinesis. Oncogene. 26:6253–6260. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Wray J, Liu J, Nickoloff JA and Shen Z: Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication stress. Cancer Res. 68:2699–2707. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Lu H, Huang YY, Mehrotra S, Droz-Rosario R, Liu J, Bhaumik M, White E and Shen Z: Essential roles of BCCIP in mouse embryonic development and structural stability of chromosomes. PLoS Genet. 7:e10022912011. View Article : Google Scholar : PubMed/NCBI
11.	Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin. 62:10–29. 2012.
12.	Jemal A, Siegel E, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 57:43–66. 2007.
13.	Sameer AS: Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 3:1142013. View Article : Google Scholar : PubMed/NCBI
14.	Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smish KD, Cushing RC and Seagroves TN: Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res. 14:R62012.
15.	McDonald PC, Winum JY, Supuran CT and Dedhar S: Recent developments in targeting carbonate anhydrase IX for cancer therapeutics. Oncotarget. 3:84–97. 2012.PubMed/NCBI
16.	Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res. 316:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Choschzick M, Oosterwijk E, Müller V, Woelber L, Simon R, Moch H and Tennstedt P: Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch. 459:193–200. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Seeber LM, Horrée N, Vooijs MA, Heintz AP, van der Wall E, Verheijen RH and van Diest PJ: The role of hypoxia inducible factor-1 alpha in gynecological cancer. Crit Rev Oncol Hematol. 78:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer; Chicago, IL: 2010
20.	Tavassoli FA and Devilee P: Patholology and genetics Tumors of the breast and female genital organs. World Health Organization Classification of Tumors. IARC Press; Lyon: 2003
21.	Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Morravan V and Swenerton K: Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 39:1239–1251. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Mostofi FK: Histological typing of kidney tumors. World Health Organization International Classification of Tumors. Springer-Verlag; New York, NY: 1998
23.	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
24.	Merlo A: Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev. 26:145–158. 2003.PubMed/NCBI
25.	Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM and Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Powell SN and Kachnic LA: Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 22:5784–5791. 2003. View Article : Google Scholar : PubMed/NCBI
27.	Daniels MJ, Wang Y, Lee M and Venkitaraman AR: Abnormal cytokinesis in cells deficient in the breast cancer susceptibility BRCA2. Science. 306:876–879. 2004. View Article : Google Scholar : PubMed/NCBI
28.	Rudkin TM and Foulkes WD: BRCA2: breaks, mistakes and failed separations. Trends Mol Med. 11:145–148. 2005. View Article : Google Scholar : PubMed/NCBI
29.	Lu H, Yue J, Meng X, Nickoloff JA and Shen Z: BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage. Necleic Acids Res. 35:7160–7170. 2007. View Article : Google Scholar : PubMed/NCBI
30.	Liu J, Lu H, Ohgaki H, Merlo A and Shen Z: Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer. 9:2682009. View Article : Google Scholar : PubMed/NCBI